This research article introduces a novel antibody-drug conjugate (ADC) designed to treat T cell cancers by targeting the TRBC2 constant region of the T cell receptor. Unlike existing treatments that deplete all T cells and cause severe immunosuppression, this therapy exploits the fact that individual T cell malignancies express only one of two possible alleles, either TRBC1 or TRBC2. By engineering a high-affinity antibody named JX1.1, the researchers successfully targeted cancerous cells while preserving a significant portion of healthy T cells to maintain immune function. Laboratory tests and animal models demonstrated that this ADC is effectively internalized by tumor cells and delivers a potent cytotoxic payload, leading to tumor regression. This selective approach offers a promising, off-the-shelf therapeutic option for patients with aggressive T cell leukemias and lymphomas.

References:

• Ge J, Urban J, DiNapoli S R, et al. TRBC2-targeting antibody–drug conjugates for the treatment of T cell cancers[J]. Nature Cancer, 2025: 1-14.